On November 9, 2026, the Board of Directors (the "Board") of Celanese Corporation (the "Company") increased the size of the Board from 11 to 12 members and elected Peter Matt as a director of the Company, in each case effective November 9, 2026. Mr. Matt has been elected to serve
On November 10, 2026, Sonic Automotive, Inc. and certain of its subsidiaries entered into a Consolidated, Amended and Restated Credit Agreement with PNC Bank, National Association, as administrative agent, and other lenders. The agreement consolidates, amends and restates the com
On November 10, 2026, Jason Kruger notified MediciNova, Inc. of his resignation as Chief Financial Officer of the Company, effective immediately. Mr. Kruger had served as the Company’s principal financial officer and principal accounting officer. Mr. Kruger’s resignat
Key PointsNvidia doesn't have a typical corporate structure, and the degree to which the now-former CEO kept power concentrated made it overly reliant on him.
Precision Optics Corporation, Inc. reported its financial results for the first quarter of fiscal 2027 ended September 30, 2026, with revenue increasing 22% to $8.2 million from $6.7 million in the prior-year fiscal first quarter. Production revenue grew 23% to $7.4 million from
Pool Corporation announced that it has signed a definitive agreement to acquire Team Horner Group, Inc., a Fort Lauderdale, Florida-based wholesale distributor of swimming pool products. Team Horner’s wholesale distribution business, which operates as HornerXpress, provides
T Stamp Inc. reported its financial results for the nine months ended September 30, 2026, with net recognized revenue increasing 28% to $2.85 million, compared to $2.23 million for the corresponding period in 2025. The company attributed the growth primarily to increased revenue
(RTTNews) - Roche Holding AG (RHHBY) announced that the U.S. Food and Drug Administration (FDA) approved Wilserdly, or giredestrant, with Everolimus for adults with breast cancer.
Peoples Financial Services Corp. reported net income of $19.1 million, or $1.90 per diluted share for the three months ended September 30, 2026. During this period, the company recorded a ROAA of 1.41%, ROATCE of 17.3%, a net interest margin (FTE) of 3.80%, and an efficiency rati
Omeros Corporation reported its financial results for the third quarter ended September 30, 2026. The company's lead product, YARTEMLEA (narsoplimab-wuug), generated gross revenue of $41.8 million in the third quarter of 2026, representing a 30% increase from $32.2 million in the
Patrick Industries, Inc. announced that its Board of Directors approved an increase in the amount of its quarterly cash dividend on its common stock to $0.52 per share from $0.47 per share. The dividend is payable on December 7, 2026, to shareholders of record at the close of bus
(RTTNews) - TRIMTECH Therapeutics, a biotechnology company developing therapies for neurodegenerative diseases, announced that it has entered into a strategic research collaboration, option, and license agreement with Biogen International GmbH (BIIB) to develop neurodegenerative
(RTTNews) - Oxford Biomedica plc (OXB.L), a gene and cell therapy company, on Tuesday confirmed its manufacturing and supply partnership with Aura Biosciences, Inc. (AURA), a biotechnology company.
Enanta Pharmaceuticals, Inc. reported its financial results for the fiscal fourth quarter and year ended September 30, 2026. Total revenue was $12.9 million for the three months ended September 30, 2026, compared to $15.1 million for the three months ended September 30, 2025, wit
The S&P 500 Index ($SPX ) (SPY ) closed down -1.92% on Monday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -1.41%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -2.67%. December E-mini S&P futures (ESZ26 ) fell -1.91%, and December E-mini Nasdaq futures...
(RTTNews) - Keros Therapeutics, Inc. (KROS), a clinical-stage biopharmaceutical company, announced that its board of directors has approved a $5 million share repurchase program.
agilon health, inc. announced a virtual investor event and presentation scheduled for Tuesday, November 17, 2026, at 2:00 PM, Eastern Time. The presentation outlines the company's clinical care framework and Total Care Model. As of December 31, 2025, the company's platform manage
Luvu Brands, Inc. reported that net sales for the quarter ended September 30, 2026, increased 10% to $6.78 million, compared to $6.16 million in the prior-year quarter. Growth was led by the Wholesale segment, which rose 12.3% to $4.72 million, driven by strong growth among adult
Tivic Health Systems, Inc. (reported as Valion Bio, Inc. in the filing) held a special meeting of stockholders on November 12, 2026. At the meeting, stockholders approved a proposal granting discretionary authority to the board of directors to amend the certificate of incorporati